Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients

Basit Öğe Kaydı
dc.contributor.authorAtalay, Huseyin
dc.contributor.authorSolak, Yalcin
dc.contributor.authorAcar, Kadir
dc.contributor.authorGovec, Nilgun
dc.contributor.authorTurk, Suleyman
dc.date.accessioned2020-03-26T18:16:01Z
dc.date.available2020-03-26T18:16:01Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractIron sucrose and low-molecular-weight iron dextran (LMW-ID), two commonly used iron solutions, have been compared in terms of allergic adverse event profiles to date. However, the safety of total dose infusion of LMW-ID has been investigated by only one study in chronic kidney disease (CKD) (not dialysis) patients. Thus, we aimed to compare adverse event profiles of total and high-dose LMW-ID and iron sucrose infusions in a heterogenous renal patient group comprising CKD, hemodialysis, and peritoneal dialysis. In this retrospective chart review study, we included 110 predialysis CKD, 101 peritoneal dialysis, and 118 hemodialysis patients. We included a total of 329 patients who were administered parenteral iron sucrose or LMW-ID between September 2006 and April 2010. Adverse events were determined both by medical and nursing follow-up notes. Laboratory data and clinical characteristics were collected from patient charts. Adverse event rates were compared between iron sucrose and LMW-ID infusions. In a total of 329 patients, 530 infusions (3470 ampules) were administered. We detected adverse reaction in only 1 patient. This adverse reaction, which manifested as generalized pruritus, occurred in a patient who received 500 mg of iron sucrose infusion. There were neither anaphylactic reactions nor deaths associated with infusion of either preparation. We did not observe any other adverse event related to administration of 500 and 1000 mg of iron sucrose at single infusion. The results of this study showed comparable safety of total dose LMW-ID and high-dose iron sucrose in a heterogenous group of renal patients.en_US
dc.identifier.doi10.1111/j.1542-4758.2011.00550.xen_US
dc.identifier.endpage378en_US
dc.identifier.issn1492-7535en_US
dc.identifier.issn1542-4758en_US
dc.identifier.issue3en_US
dc.identifier.pmid21564503en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage374en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1542-4758.2011.00550.x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26795
dc.identifier.volume15en_US
dc.identifier.wosWOS:000292314900011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofHEMODIALYSIS INTERNATIONALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectIron sucroseen_US
dc.subjectlow-molecular-weight iron dextranen_US
dc.subjectrenal patientsen_US
dc.subjecttotal dose infusionen_US
dc.titleSafety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu